Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04625946 · ClinicalTrials.gov registry record · Phase 4
Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation
A Phase 4 study of Atrial Fibrillation, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 117
- Enrollment target
- 1
- Study location
NCT04625946 is a Phase 4 study of Atrial Fibrillation that has completed, run by University of Michigan. The registered enrollment target is 117 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04625946, a Phase 4 study of Atrial Fibrillation, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 117 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial is being done to determine if metformin, a drug which is normally used in diabetes, can reduce atrial fibrillation in patients who are having an ablation for atrial fibrillation (AF). Atrial fibrillation is an abnormal heart rhythm which research has shown is related in part to obesity and diabetes. It is anticipated that the participants treated in the metformin arm will have greater freedom from recurrent atrial arrhythmias after ablation. Eligible participants enrolled in the trial will be assigned to one of the treatment arms (no treatment or metformin) and have follow-up visits up to approximately 1 year after the ablation. Additionally, all patients will also receive education on lifestyle changes and exercise which are standard of care.
Conditions Studied
Interventions
- DRUG Metformin
- DEVICE AliveCor
- BEHAVIORAL Recommendations for lifestyle modification.
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2021-01-19 |
| Est. Completion | 2025-08-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04625946
The ClinicalTrials.gov registry entry for NCT04625946 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (96% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 3 interventions - of which Metformin is the first listed.
NCT04625946 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT04625946 about?
NCT04625946 is a clinical study titled "Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation". This clinical trial is being done to determine if metformin, a drug which is normally used in diabetes, can reduce atrial fibrillation in patients who are having an ablation for atrial fibrillation (AF). Atrial fibrillation is an abnormal heart rhythm which research has shown is related in part to o...
What is the current status of trial NCT04625946?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 117 participants. The study started on 2021-01-19. Estimated completion is 2025-08-10.
What conditions does trial NCT04625946 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT04625946?
The interventions under investigation include: Metformin (DRUG), AliveCor (DEVICE), Recommendations for lifestyle modification. (BEHAVIORAL).
Who is sponsoring clinical trial NCT04625946?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04625946 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
ACTIVE NOT RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.